-
1.发明申请DEVICES AND METHODS FOR TREATMENT OF THE EUSTACHIAN TUBE AND SINUS CAVITY 审中-公开用于治疗EUSTACHIAN TUBE和SINUS CAVITY的装置和方法公开(公告)号：US20170027724A1
公开(公告)日：2017-02-02
申请号：US15290886
申请日：2016-10-11
Applicant: Abbott Cardiovascular Systems Inc.
Inventor： Syed Hossainy , Paul Consigny , Dariush Davalian , James Su , Michael Ngo , Adrain Gale , Jesus Magana , Mikael Trollsas , Evan Norton , Benjamyn Serna
CPC classification number: A61F2/958 , A61B1/06 , A61F2/915 , A61F11/002 , A61F2002/91575 , A61F2002/91583 , A61F2230/0067 , A61F2250/0018 , A61F2250/0026 , A61F2250/0046 , A61F2250/0048 , A61F2250/005 , A61F2250/0082 , A61M25/10 , A61M29/02 , A61M2025/105 , A61M2025/1059 , A61M2210/0675
Abstract: A polymeric stent can be implanted for treatment of the Eustachian tube. The stent can be designed to have length-dependent radial strength to allow it to stay within the Eustachian tube and to allow normal closing and opening of the Eustachian tube. A balloon can be used to implant the stent, and the balloon can be coated with a therapeutic agent. A coated balloon can also be used to transfer therapeutic agents to the sinus cavity during a balloon sinus dilation procedure.
Abstract translation: 可以植入聚合物支架以治疗咽鼓管。 支架可以设计成具有长度依赖的径向强度，以允许其保持在咽鼓管内并允许正常的关闭和打开咽鼓管。 可以使用气囊来植入支架，并且可以用治疗剂涂覆气囊。 在气球窦扩张过程中，涂覆的气囊也可以用于将治疗剂转移到窦腔。
-
公开(公告)号：US20160158060A1
公开(公告)日：2016-06-09
申请号：US15008279
申请日：2016-01-27
Applicant: Abbott Cardiovascular Systems Inc.
Inventor： John Stankus , James Su
IPC: A61F9/00
CPC classification number: A61F9/0017
Abstract: An ophthalmic shunt includes a seal or septum through which multiple injections of the therapeutic agent can be made as needed, thereby avoiding repeated injury to the sclera. The therapeutic agent is temporarily carried in a tube connected to the septum. The therapeutic agent release may be rapid or sustained over a period of time.
Abstract translation: 眼科分流器包括密封件或隔膜，根据需要多次注射治疗剂，从而避免对巩膜的重复损伤。 治疗剂临时携带在连接到隔膜的管中。 治疗剂释放可能在一段时间内快速或持续。
-
公开(公告)号：US20140336619A1
公开(公告)日：2014-11-13
申请号：US13893055
申请日：2013-05-13
Applicant: Abbott Cardiovascular Systems Inc.
Inventor： John Stankus , James Su
IPC: A61F9/00
CPC classification number: A61F9/0017
Abstract: An ophthalmic shunt includes a seal or septum through which multiple injections of the therapeutic agent can be made as needed, thereby avoiding repeated injury to the sclera. The therapeutic agent is temporarily carried in a tube connected to the septum. The therapeutic agent release may be rapid or sustained over a period of time.
Abstract translation: 眼科分流器包括密封件或隔膜，根据需要多次注射治疗剂，从而避免对巩膜的重复损伤。 治疗剂临时携带在连接到隔膜的管中。 治疗剂释放可能在一段时间内快速或持续。
-
公开(公告)号：US20140186446A1
公开(公告)日：2014-07-03
申请号：US14142651
申请日：2013-12-27
Applicant: Abbott Cardiovascular Systems Inc.
Inventor： Mikael Trollsas , John Stankus , James Su , Syed Hossainy , Joshua Takeshi Smith , Shadid Askar
CPC classification number: A61K9/146 , A61K9/0019 , A61K9/06 , A61K9/08 , A61K38/215 , A61K47/10 , A61K2039/505 , C07K16/241 , C07K16/40 , C07K2317/21
Abstract: Formulations and methods are disclosed which provide controlled, sustained release of a biologic therapeutic to a space within the body. More specifically, formulations comprising a plurality of hydrophilic polymer strands, and methods of forming and administering such formulations, are disclosed. In some embodiments, the formulations exhibit a burst release, an initial release, a triphasic release, and release over thirty to ninety days of the biologic therapeutic. In some embodiments, the formulations exhibit reversible precipitation of the biologic therapeutic into precipitates having a diameter of about 50 nm to about 10 μm.
Abstract translation: 公开了提供对体内空间的生物治疗剂的受控的持续释放的制剂和方法。 更具体地，公开了包含多个亲水性聚合物链的制剂，以及形成和施用这些制剂的方法。 在一些实施方案中，制剂在生物治疗的三十至九十天内显示爆发释放，初始释放，三相释放和释放。 在一些实施方案中，制剂将生物治疗剂的可逆沉淀显示为具有约50nm至约10μm直径的沉淀物。
-
Patent Agency Ranking
公开(公告)号：US09907695B2
公开(公告)日：2018-03-06
申请号：US15008279
申请日：2016-01-27
Applicant: Abbott Cardiovascular Systems Inc.
Inventor： John Stankus , James Su
CPC classification number: A61F9/0017
Abstract: An ophthalmic shunt includes a seal or septum through which multiple injections of the therapeutic agent can be made as needed, thereby avoiding repeated injury to the sclera. The therapeutic agent is temporarily carried in a tube connected to the septum. The therapeutic agent release may be rapid or sustained over a period of time.
-
公开(公告)号：US20170042816A1
公开(公告)日：2017-02-16
申请号：US15242403
申请日：2016-08-19
Applicant: Abbott Cardiovascular Systems Inc.
Inventor： Mikael Trollsas , John Stankus , James Su , Syed Hossainy , Joshua Takeshi Smith , Shadid Askar
CPC classification number: A61K9/146 , A61K9/0019 , A61K9/06 , A61K9/08 , A61K38/215 , A61K47/10 , A61K2039/505 , C07K16/241 , C07K16/40 , C07K2317/21
Abstract: Formulations and methods are disclosed which provide controlled, sustained release of a biologic therapeutic to a space within the body. More specifically, formulations comprising a plurality of hydrophilic polymer strands, and methods of forming and administering such formulations, are disclosed. In some embodiments, the formulations exhibit a burst release, an initial release, a triphasic release, and release over thirty to ninety days of the biologic therapeutic. In some embodiments, the formulations exhibit reversible precipitation of the biologic therapeutic into precipitates having a diameter of about 50 nm to about 10 μm.
Abstract translation: 公开了提供对体内空间的生物治疗剂的受控的持续释放的制剂和方法。 更具体地，公开了包含多个亲水性聚合物链的制剂，以及形成和施用这些制剂的方法。 在一些实施方案中，制剂在生物治疗的三十至九十天内显示爆发释放，初始释放，三相释放和释放。 在一些实施方案中，制剂将生物治疗剂的可逆沉淀显示为具有约50nm至约10μm直径的沉淀物。
-
7.发明授权公开(公告)号：US09510976B2
公开(公告)日：2016-12-06
申请号：US14265343
申请日：2014-04-29
Applicant: ABBOTT CARDIOVASCULAR SYSTEMS INC.
Inventor： Syed Hossainy , Paul Consigny , Dariush Davalian , James Su , Michael Ngo , Adrain Gale , Jesus Magana , Mikael Trollsas , Evan Norton , Benjamyn Serna
CPC classification number: A61F2/958 , A61B1/06 , A61F2/915 , A61F11/002 , A61F2002/91575 , A61F2002/91583 , A61F2230/0067 , A61F2250/0018 , A61F2250/0026 , A61F2250/0046 , A61F2250/0048 , A61F2250/005 , A61F2250/0082 , A61M25/10 , A61M29/02 , A61M2025/105 , A61M2025/1059 , A61M2210/0675
Abstract: A polymeric stent can be implanted for treatment of the Eustachian tube. The stent can be designed to have length-dependent radial strength to allow it to stay within the Eustachian tube and to allow normal closing and opening of the Eustachian tube. A balloon can be used to implant the stent, and the balloon can be coated with a therapeutic agent. A coated balloon can also be used to transfer therapeutic agents to the sinus cavity during a balloon sinus dilation procedure.
Abstract translation: 可以植入聚合物支架以治疗咽鼓管。 支架可以设计成具有长度依赖的径向强度，以允许其保持在咽鼓管内并允许正常的关闭和打开咽鼓管。 可以使用气囊来植入支架，并且可以用治疗剂涂覆气囊。 在气球窦扩张过程中，涂覆的气囊也可以用于将治疗剂转移到窦腔。
-
公开(公告)号：US09452138B2
公开(公告)日：2016-09-27
申请号：US14142651
申请日：2013-12-27
Applicant: Abbott Cardiovascular Systems Inc.
Inventor： Mikael Trollsas , John Stankus , James Su , Syed Hossainy , Joshua Takeshi Smith , Shadid Askar
IPC: A61K38/00 , A61K9/14 , A61K9/00 , A61K47/10 , A61K9/08 , C07K16/24 , C07K16/40 , A61K38/21 , A61K39/00
CPC classification number: A61K9/146 , A61K9/0019 , A61K9/06 , A61K9/08 , A61K38/215 , A61K47/10 , A61K2039/505 , C07K16/241 , C07K16/40 , C07K2317/21
Abstract: Formulations and methods are disclosed which provide controlled, sustained release of a biologic therapeutic to a space within the body. More specifically, formulations comprising a plurality of hydrophilic polymer strands, and methods of forming and administering such formulations, are disclosed. In some embodiments, the formulations exhibit a burst release, an initial release, a triphasic release, and release over thirty to ninety days of the biologic therapeutic. In some embodiments, the formulations exhibit reversible precipitation of the biologic therapeutic into precipitates having a diameter of about 50 nm to about 10 μm.
Abstract translation: 公开了提供对体内空间的生物治疗剂的受控的持续释放的制剂和方法。 更具体地，公开了包含多个亲水性聚合物链的制剂，以及形成和施用这些制剂的方法。 在一些实施方案中，制剂在生物治疗的三十至九十天内显示爆发释放，初始释放，三相释放和释放。 在一些实施方案中，制剂将生物治疗剂的可逆沉淀显示为具有约50nm至约10μm直径的沉淀物。
-
9.发明申请公开(公告)号：US20150305943A1
公开(公告)日：2015-10-29
申请号：US14265343
申请日：2014-04-29
Applicant: ABBOTT CARDIOVASCULAR SYSTEMS INC.
Inventor： Syed Hossainy , Paul Consigny , Dariush Davalian , James Su , Michael Ngo , Adrain Gale , Jesus Magana , Mikael Trollsas , Evan Norton , Benjamyn Serna
CPC classification number: A61F2/958 , A61B1/06 , A61F2/915 , A61F11/002 , A61F2002/91575 , A61F2002/91583 , A61F2230/0067 , A61F2250/0018 , A61F2250/0026 , A61F2250/0046 , A61F2250/0048 , A61F2250/005 , A61F2250/0082 , A61M25/10 , A61M29/02 , A61M2025/105 , A61M2025/1059 , A61M2210/0675
Abstract: A polymeric stent can be implanted for treatment of the Eustachian tube. The stent can be designed to have length-dependent radial strength to allow it to stay within the Eustachian tube and to allow normal closing and opening of the Eustachian tube. A balloon can be used to implant the stent, and the balloon can be coated with a therapeutic agent. A coated balloon can also be used to transfer therapeutic agents to the sinus cavity during a balloon sinus dilation procedure.
Abstract translation: 可以植入聚合物支架以治疗咽鼓管。 支架可以被设计成具有长度依赖的径向强度，以允许其停留在咽鼓管内并允许正常的关闭和打开咽鼓管。 可以使用气囊来植入支架，并且可以用治疗剂涂覆气囊。 在气球窦扩张过程中，涂覆的气囊也可以用于将治疗剂转移到窦腔。
-
-
-
-
-
-
-
-
Search Results
9
records
(took 0.024 seconds)
